Avalon GloboCare Announces the Deployment of Breakthrough Fusion Gene Map Technology
03 janv. 2023 09h00 HE
|
Avalon GloboCare Corp.
FREEHOLD, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a leading global developer of innovative cell-based technologies and therapeutics...
Avalon GloboCare Announces $4 Million Private Placement of Preferred Stock with the Company’s Chairman which Converts at a Significant Premium to Market; Proceeds to Support Acquisition of Laboratory Services
14 déc. 2022 09h00 HE
|
Avalon GloboCare Corp.
Newly issued preferred stock convertible at a minimum of $1.00 per share, with leak-out provisions, no warrants and a 9-month lock up Laboratory Services acquisition expected to close within 30...
Avalon GloboCare Continues its U.S. Centric Strategy with a New Proposed Board Composition in Preparation for Acquisition of Laboratory Services MSO, LLC
12 déc. 2022 09h00 HE
|
Avalon GloboCare Corp.
Company Discontinues China Operations, Reducing Cash Burn Encourages Shareholders to Vote in the Upcoming Annual Shareholder Meeting on December 29th FREEHOLD, N.J., Dec. 12, 2022 (GLOBE NEWSWIRE)...
Avalon GloboCare Announces NASDAQ Ticker Symbol Change from “AVCO” to “ALBT”
09 nov. 2022 16h00 HE
|
Avalon GloboCare Corp.
Company to Begin Trading under New Symbol “ALBT” on November 10, 2022 Symbol Change Better Reflects Avalon’s New Focus on Laboratory Services and Biotherapeutics FREEHOLD, N.J., Nov. 09, 2022 ...
Avalon GloboCare Signs Definitive Agreement for Transformational Acquisition of Leading Laboratory with 2021 Unaudited Revenue in Excess of $25 Million
08 nov. 2022 09h10 HE
|
Avalon GloboCare Corp.
Company to acquire a majority interest in Laboratory Services MSO, LLC, a leading reference laboratory with 2021 unaudited revenue in excess of $25 million, net income in excess of $10 million and...
Avalon GloboCare Receives Allowance for Joint U.S. Patent
29 sept. 2022 09h00 HE
|
Avalon GloboCare Corp.
FREEHOLD, N.J., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, today provided an update...
Avalon GloboCare Announces Publication Featuring QTY Code Technology in the Official Journal of the American Chemical Society
08 août 2022 09h00 HE
|
Avalon GloboCare Corp.
Findings support utility of QTY protein code as a novel platform to generate water-soluble proteins for wide spectrum of biomedical applications Reports plans to apply for additional patents...
Avalon GloboCare Announces New Study Featuring AI-Enhanced Protein Design Technology Targeting Glucose Transporter Against Cancer
30 juin 2022 09h00 HE
|
Avalon GloboCare Corp.
FREEHOLD, N.J., June 30, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, today announced a new...
Avalon GloboCare to Present at the Jefferies 2022 Healthcare Conference
25 mai 2022 09h00 HE
|
Avalon GloboCare Corp.
FREEHOLD, N.J., May 25, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, announced today that David...
Avalon GloboCare Signs MOU to Form Strategic Partnership with Lu Daopei Hematology Institute to Develop Precision Companion Diagnostics for Cellular Therapy
18 mai 2022 09h00 HE
|
Avalon GloboCare Corp.
Goal of Partnership is to expand Avalon’s R&D pipeline to include innovative companion diagnostics in association with the company’s ongoing and future cellular immunotherapy clinical programs ...